Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03067051 · ClinicalTrials.gov registry record · Phase 1
Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System
A Phase 1 study of Recurrent Prostate Cancer, sponsored by SpectraCure AB.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 66
- Enrollment target
- 4
- Study locations
NCT03067051: Recruiting Phase 1 study of Recurrent Prostate Cancer, sponsored by SpectraCure AB.
NCT03067051 is a Phase 1 study of Recurrent Prostate Cancer that is actively recruiting participants, run by SpectraCure AB. The registered enrollment target is 66 participants, below the 136-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (51% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03067051, a Phase 1 study of Recurrent Prostate Cancer, is actively recruiting participants, sponsored by SpectraCure AB.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 66 participants
- Enrollment target
- 4
- Study locations
Study Summary
The rationale for the study is to obtain safety and efficacy data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.
Primary Outcome
Dose limiting toxicities are defined as grade 3 non-hematologic or grade 4 hematologic toxicities that are possibly, probably or definitely related to PDT.
Conditions Studied
Interventions
- DRUG Verteporfin
- DEVICE SpectraCure P18 System
Study Locations (4)
New York
- Memorial Sloan Kettering Cancer Center - New York
Ontario
- Princess Margaret Cancer Centre - Toronto
Skåne County
- Skåne University Hospital - Malmo
Other
- Reader in Urology, University College London & Honorary Consultant Urological Surgeon, University College London Hospitals Trust - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2017-03-21 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT03067051 shows while recruiting
NCT03067051 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 66 participants, a relatively small participant target, below the 136-participant average among 21 other Recurrent Prostate Cancer trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Recurrent Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Verteporfin is the first listed.
NCT03067051 reports a single indexed study location in New York, Ontario, Skåne County.
Frequently Asked Questions
What is clinical trial NCT03067051 about?
NCT03067051 is a clinical study titled "Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System". The rationale for the study is to obtain safety and efficacy data as well as to establish dose parameters for the SpectraCure P18 System with IDOSE®, with verteporfin for injection (VFI) as photosensitizer for the treatment of recurrent prostate cancer.
What is the current status of trial NCT03067051?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 66 participants. The study started on 2017-03-21. Estimated completion is 2026-12-31.
What conditions does trial NCT03067051 study?
This clinical trial studies the following conditions: Recurrent Prostate Cancer.
What interventions are being tested in trial NCT03067051?
The interventions under investigation include: Verteporfin (DRUG), SpectraCure P18 System (DEVICE).
Who is sponsoring clinical trial NCT03067051?
This trial is sponsored by SpectraCure AB, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03067051 being conducted?
This trial has 4 study locations across New York, Ontario, Skåne County. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03067051's enrollment target sits among peer trials
66 8th of 21 higher than 14 of 21 other Recurrent Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
RECRUITING · Phase 1
-
Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery
ACTIVE NOT RECRUITING · Phase 1
-
High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02584244 · 66 participants · Phase 1
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
- NCT03754725 · 66 participants · Phase 1
Ferritin and Iron Burden in SAH sIRB
- NCT03875378 · 66 participants · Phase 2
Transdermal Estrogen in Women With Anorexia Nervosa
- NCT04029623 · 66 participants · NA
Partnered Rhythmic Rehabilitation in Prodromal Alzheimer's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI